Critical Review: EOM Pharmaceutical (OTCMKTS:IMUC) and FibroGen (NASDAQ:FGEN)

FibroGen (NASDAQ:FGEN) and EOM Pharmaceutical (OTCMKTS:IMUC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations for FibroGen and EOM Pharmaceutical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroGen	1	1	1	0	2.00
EOM Pharmaceutical	0	0	0	0	0.00

FibroGen currently has a consensus price target of $43.00, suggesting a potential upside of 340.12%. Given FibroGen’s stronger consensus rating and higher probable upside, research analysts clearly believe FibroGen is more favorable than EOM Pharmaceutical.

Volatility & Risk

FibroGen has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, EOM Pharmaceutical has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500.

Profitability

This table compares FibroGen and EOM Pharmaceutical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
FibroGen	2,598.55%	N/A	-26.27%
EOM Pharmaceutical	N/A	N/A	N/A

Institutional & Insider Ownership

72.7% of FibroGen shares are held by institutional investors. 3.1% of FibroGen shares are held by insiders. Comparatively, 3.3% of EOM Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares FibroGen and EOM Pharmaceutical”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FibroGen	$29.62 million	1.34	-$47.58 million	$53.48	0.18
EOM Pharmaceutical	N/A	N/A	-$1.89 million	N/A	N/A

EOM Pharmaceutical has lower revenue, but higher earnings than FibroGen.

Summary

FibroGen beats EOM Pharmaceutical on 7 of the 10 factors compared between the two stocks.

About FibroGen

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

About EOM Pharmaceutical

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.